In this study, we report that continued use of trastuzumab to induce resistance in PTEN deficient HER2+ breast cancer results in the epithelial to mesenchymal transition (EMT), as evident by reduced expression of epithelial markers and increased mesenchymal makers. This evidence concerns the gene ERBB2 and breast cancer.